Integrated Filing — IndAS



General information about company
Scrip Code 524494
NSE Symbol IPCALAB
MSEI Symbol NOTLISTED
ISIN INE571A01038
Name of company IPCA LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-May-2025   11:30:00
End date and time of board meeting 29-May-2025   13:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-11-14
Indicate Company website link for updated RPT policy of the Company www.ipca.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company has not defaulted on loans and debt securities



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 16384400000 66779200000
Other income 214900000 712900000
Total income 16599300000 67492100000
2 Expenses
(a) Cost of materials consumed 3516700000 14176400000
(b) Purchases of stock-in-trade 790600000 3472400000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 147900000 1284300000
(d) Employee benefit expense 3771200000 14793400000
(e) Finance costs 162000000 630400000
(f) Depreciation, depletion and amortisation expense 651900000 2519700000
(f) Other Expenses
1 Other Expenses 4572100000 17802400000
Total other expenses 4572100000 17802400000
Total expenses 13612400000 54679000000
3 Total profit before exceptional items and tax 2986900000 12813100000
4 Exceptional items -2815400000 -2815400000
5 Total profit before tax 171500000 9997700000
6 Tax expense
7 Current tax 759000000 3409000000
8 Deferred tax 63000000 81100000
9 Total tax expenses 822000000 3490100000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -650500000 6507600000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -650500000 6507600000
17 Other comprehensive income net of taxes 25700000 -63700000
18 Total Comprehensive Income for the period -624800000 6443900000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 253700000 253700000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 68662500000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.56 25.65
Diluted earnings (loss) per share from continuing operations -2.56 25.65
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.56 25.65
Diluted earnings (loss) per share from continuing and discontinued operations -2.56 25.65
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 25027800000
Capital work-in-progress 4840500000
Investment property 0
Goodwill 77700000
Other intangible assets 261600000
Intangible assets under development 56000000
Biological assets other than bearer plants 2600000
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 20413200000
Trade receivables, non-current 0
Loans, non-current 319600000
Other non-current financial assets 837900000
Total non-current financial assets 21570700000
Deferred tax assets (net) 0
Other non-current assets 691800000
Total non-current assets 52528700000
2 Current assets
Inventories 15423900000
Current financial asset
Current investments 6519400000
Trade receivables, current 11546100000
Cash and cash equivalents 767700000
Bank balance other than cash and cash equivalents 877600000
Loans, current 403700000
Other current financial assets 331000000
Total current financial assets 20445500000
Current tax assets (net)
Other current assets 1930000000
Total current assets 37799400000
3 Non-current assets classified as held for sale 381100000
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 90709200000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 253700000
Other equity 68662500000
Total equity attributable to owners of parent 68916200000
Non controlling interest
Total equity 68916200000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 4824300000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 283800000
Total non-current financial liabilities 5108100000
Provisions, non-current 577600000
Deferred tax liabilities (net) 1912000000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 7597700000
Current liabilities
Current financial liabilities
Borrowings, current 3893000000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 911500000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 3903800000
Total Trade payable 4815300000
Other current financial liabilities 3143700000
Total current financial liabilities 11852000000
Other current liabilities 577300000
Provisions, current 1311000000
Current tax liabilities (Net) 435700000
Deferred government grants, Current 0
Total current liabilities 14176000000
3 Liabilities directly associated with assets in disposal group classified as held for sale 19300000
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 21793000000
Total equity and liabilites 90709200000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Actuarial gain/(loss) 22600000 -68200000
2 Fair value change through other comprehansive Income 4400000 4400000
Total Amount of items that will not be reclassified to profit and loss 27000000 -63800000
2 Income tax relating to items that will not be reclassified to profit or loss 5500000 -19000000
3 Amount of items that will be reclassified to profit and loss
1 Exchange diffrence in translating the financial statement of foreign operation 5400000 -26200000
Total Amount of items that will be reclassified to profit and loss 5400000 -26200000
4 Income tax relating to items that will be reclassified to profit or loss 1200000 -7300000
5 Total Other comprehensive income 25700000 -63700000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 9997700000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 630400000
Adjustments for decrease (increase) in inventories 1329500000
Adjustments for decrease (increase) in trade receivables, current -1332700000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 87100000
Adjustments for decrease (increase) in other non-current assets 19500000
Adjustments for other financial assets, non-current -13400000
Adjustments for other financial assets, current 347600000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 578000000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 31200000
Adjustments for increase (decrease) in other non-current liabilities -1200000
Adjustments for depreciation and amortisation expense 2519700000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 90200000
Adjustments for provisions, non-current 72700000
Adjustments for other financial liabilities, current -275800000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 59000000
Adjustments for dividend income 0
Adjustments for interest income 247100000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) -13700000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 3109500000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 6990500000
Net cash flows from (used in) operations 16988200000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 3247500000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 13740700000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 928900000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 272000000
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 62500000
Proceeds from sales of property, plant and equipment 45500000
Purchase of property, plant and equipment 6026000000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 500000
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 247500000
Cash receipts from repayment of advances and loans made to other parties 320800000
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 143300000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -360300000
Net cash flows from (used in) investing activities -7388100000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 1679800000
Repayments of borrowings 4357200000
Payments of lease liabilities 101000000
Dividends paid 1014800000
Interest paid 491200000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -4284400000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 2068200000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 2068200000
Cash and cash equivalents cash flow statement at beginning of period 5152800000
Cash and cash equivalents cash flow statement at end of period 7221000000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Natvarlal Vepari & Co. LLP Yes 31-Jul-2027


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Ipca Laboratories Ltd AVIK PHARMACEUTICAL LTD. Joint Ventures Purchase of goods or services Approved 169600000 18200000 7300000
2 Ipca Laboratories Ltd AVIK PHARMACEUTICAL LTD. Joint Ventures Interest received Approved 5000000 0 700000
3 Ipca Laboratories Ltd AVIK PHARMACEUTICAL LTD. Joint Ventures Any other transaction Expenses Reimbursement Approved -1100000 0 0
4 Ipca Laboratories Ltd AVIK PHARMACEUTICAL LTD. Joint Ventures Loan Approved -13700000 99000000 85300000 Loan 0.11 5 years Unsecured Business Purpose
5 Ipca Laboratories Ltd IPCA FOUNDATION Other Related Party Any other transaction Donation CSR Approved 39700000 0 0
6 Ipca Laboratories Ltd Kaygee Investments Pvt. Ltd. Promoter Dividend paid Approved 217900000 0 0
7 Ipca Laboratories Ltd KAYGEE LABORATORIES PVT. LTD. Promoter Purchase of goods or services Approved 12000000 0 2000000
8 Ipca Laboratories Ltd KAYGEE LABORATORIES PVT. LTD. Promoter Sale of goods or services Approved 100000 0 0
9 Ipca Laboratories Ltd KAYGEE LABORATORIES PVT. LTD. Promoter Any other transaction Expenses Paid Approved 0 0 0
10 Ipca Laboratories Ltd KAYGEE LABORATORIES PVT. LTD. Promoter Dividend paid Approved 67100000 0 0
11 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Purchase of goods or services Approved 298400000 10300000 0
12 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Sale of goods or services Approved 2400000 9800000 1300000
13 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Interest received Approved 27700000 105800000 130600000
14 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Sale of fixed assets Approved 3600000 0 0
15 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Any other transaction Lease Rent Approved 5100000 0 0
16 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Any other transaction Expenses Reimbursement Approved -1200000 0 0
17 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Loan Approved 73500000 649000000 722500000 Loan 0.08 3 years Unsecured Business Purpose
18 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Any other transaction Corporate Guarantee Given Approved 0 110000000 110000000
19 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Advance Approved -98500000 243300000 144800000
20 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Any other transaction Deposit Approved 0 450000000 450000000
21 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Any other transaction Expected Creidt Loss on Loan Given Approved -144500000 0 0
22 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Any other transaction Expected Creidt Loss of Interest Recievable on Loan Given Approved -130600000 0 0
23 Ipca Laboratories Ltd KREBS BIOCHEMICALS & INDUSTRIES LTD. Associates Any other transaction Impairment in Investment Approved -1085400000 0 0
24 Ipca Laboratories Ltd LYKA LABS LTD Joint Ventures Purchase of goods or services Approved 134300000 31500000 64800000
25 Ipca Laboratories Ltd LYKA LABS LTD Joint Ventures Interest received Approved 900000 0 0
26 Ipca Laboratories Ltd LYKA LABS LTD Joint Ventures Purchase of fixed assets Approved 23000000 0 0
27 Ipca Laboratories Ltd LYKA LABS LTD Joint Ventures Any other transaction Expenses Paid Approved 5600000 0 0
28 Ipca Laboratories Ltd LYKA LABS LTD Joint Ventures Loan Approved 40000000 0 40000000 Loan 0.11 6 months Unsecured Business Purpose
29 Ipca Laboratories Ltd MAKERS LABORATORIES LTD. Promoter Purchase of goods or services Approved 35800000 1800000 2600000
30 Ipca Laboratories Ltd MAKERS LABORATORIES LTD. Promoter Sale of goods or services Approved 3800000 3200000 2400000
31 Ipca Laboratories Ltd MAKERS LABORATORIES LTD. Promoter Any other transaction Rent Received Approved 2000000 0 0
32 Ipca Laboratories Ltd MAKERS LABORATORIES LTD. Promoter Any other transaction Rent Paid Approved 9300000 0 0
33 Ipca Laboratories Ltd MAKERS LABORATORIES LTD. Promoter Any other transaction Expenses Reimbursement Approved -600000 0 0
34 Ipca Laboratories Ltd MAKERS LABORATORIES LTD. Promoter Advance Approved 11000000 4000000 15000000
35 Ipca Laboratories Ltd NIPRA INDUSTRIES PVT. LTD. Other Related Party Purchase of goods or services Approved 15300000 3400000 3600000
36 Ipca Laboratories Ltd MEXIN MEDICAMENTS PVT. LTD. Promoter Dividend paid Approved 100000 0 0
37 Ipca Laboratories Ltd PASCHIM CHEMICALS PVT LTD. Promoter Dividend paid Approved 40700000 0 0
38 Ipca Laboratories Ltd RESONANCE SPECIALITIES LIMITED Other Related Party Purchase of goods or services Approved 3200000 1400000 800000
39 Ipca Laboratories Ltd RESONANCE SPECIALITIES LIMITED Other Related Party Any other transaction Rent Income Approved 300000 0 0
40 Ipca Laboratories Ltd TROPHIC WELLNESS PVT. LTD. Subsidiaries Sale of goods or services Approved 10800000 2800000 3300000
41 Ipca Laboratories Ltd TROPHIC WELLNESS PVT. LTD. Subsidiaries Any other transaction Rent Income Approved 1300000 0 0
42 Ipca Laboratories Ltd TROPHIC WELLNESS PVT. LTD. Subsidiaries Any other transaction Expenses Reimbursement Approved -100000 0 0
43 Ipca Laboratories Ltd UNICHEM LABORATORIES LTD. Subsidiaries Purchase of goods or services Approved 900000 29100000 8600000
44 Ipca Laboratories Ltd UNICHEM LABORATORIES LTD. Subsidiaries Sale of goods or services Approved 45000000 21700000 172400000
45 Ipca Laboratories Ltd UNICHEM LABORATORIES LTD. Subsidiaries Any other transaction Rent Income Approved 6900000 0 0
46 Ipca Laboratories Ltd UNICHEM LABORATORIES LTD. Subsidiaries Purchase of fixed assets Approved 21000000 0 0
47 Ipca Laboratories Ltd UNICHEM LABORATORIES LTD. Subsidiaries Sale of fixed assets Approved 300000 0 0
48 Ipca Laboratories Ltd UNICHEM LABORATORIES LTD. Subsidiaries Any other transaction Expenses Reimbursement Approved -700000 0 0
49 Ipca Laboratories Ltd UNICHEM LABORATORIES LTD. Subsidiaries Any other transaction Commitments of Share Purchase of Unichem Ireland Approved 40000000 0 0
50 Ipca Laboratories Ltd VANDHARA RESORTS PVT. LTD. Other Related Party Purchase of goods or services Approved 5700000 600000 2300000
51 Ipca Laboratories Ltd VANDHARA RESORTS PVT. LTD. Other Related Party Interest paid Approved 100000 0 0
52 Ipca Laboratories Ltd IPCA LABORATORIES UK LTD Subsidiaries Sale of goods or services Approved 583500000 555100000 587400000
53 Ipca Laboratories Ltd IPCA PHARMA (AUSTRALIA) PTY LTD. Subsidiaries Any other transaction Expenses Paid and Recovered Approved 4300000 500000 700000
54 Ipca Laboratories Ltd IPCA PHARMA NIGERIA LTD. Subsidiaries Sale of goods or services Approved 15000000 10400000 3000000
55 Ipca Laboratories Ltd IPCA PHARMACEUTICALS, INC. USA Subsidiaries Purchase of goods or services Approved 95500000 49300000 51800000
56 Ipca Laboratories Ltd IPCA PHARMACEUTICALS, INC. USA Subsidiaries Any other transaction Investments in Shares Approved 386000000 0 0
57 Ipca Laboratories Ltd IPCA PHARMACEUTICALS, INC. USA Subsidiaries Any other transaction Redemption of Shares Approved -474800000 0 0
58 Ipca Laboratories Ltd IPCA PHARMACEUTICALS, INC. USA Subsidiaries Any other transaction Impairment in Investment Approved -1730000000 0 0
59 Ipca Laboratories Ltd UNICHEM FARMACEUICA DO BRASIL LTDA Subsidiaries Purchase of goods or services Approved 100000 0 0
60 Ipca Laboratories Ltd UNICHEM PHARMACEUTICALS (USA), INC. Subsidiaries Sale of goods or services Approved 320200000 0 548100000
61 Ipca Laboratories Ltd UNICHEM PHARMACEUTICALS (USA), INC. Subsidiaries Any other transaction Unbilled Receivables Approved 14400000 0 0
62 Ipca Laboratories Ltd MR. PREMCHAND GODHA Key Management Personnel Remuneration Approved 64200000 38500000 72200000
63 Ipca Laboratories Ltd MR. AJIT KUMAR JAIN Key Management Personnel Remuneration Approved 44800000 22300000 42300000
64 Ipca Laboratories Ltd MR.PRANAY GODHA Key Management Personnel Remuneration Approved 41400000 24400000 47200000
65 Ipca Laboratories Ltd MR. PRASHANT GODHA Key Management Personnel Remuneration Approved 32700000 20500000 38600000
66 Ipca Laboratories Ltd MR. VIVEK KESHAV SHIRALKAR Key Management Personnel Any other transaction Sitting Fees Approved 800000 0 0
67 Ipca Laboratories Ltd DR. NARENDRA MAIRPADY Key Management Personnel Any other transaction Sitting Fees Approved 800000 0 0
68 Ipca Laboratories Ltd MR. KAMAL KISHORE SETH Key Management Personnel Any other transaction Sitting Fees Approved 1000000 0 0
69 Ipca Laboratories Ltd DR. (MRS.) SWATI PATANKAR Key Management Personnel Any other transaction Sitting Fees Approved 800000 0 0
70 Ipca Laboratories Ltd MR. PREMCHAND GODHA Key Management Personnel Any other transaction Provident Fund to Directors Approved 2800000 0 0
71 Ipca Laboratories Ltd MR. AJIT KUMAR JAIN Key Management Personnel Any other transaction Provident Fund to Directors Approved 2900000 0 0
72 Ipca Laboratories Ltd MR.PRANAY GODHA Key Management Personnel Any other transaction Provident Fund to Directors Approved 2500000 0 0
73 Ipca Laboratories Ltd MR. PRASHANT GODHA Key Management Personnel Any other transaction Provident Fund to Directors Approved 2000000 0 0
74 Ipca Laboratories Ltd MR. AJIT KUMAR JAIN Key Management Personnel Any other transaction Post employment benefits of Directors Approved 2300000 0 0
75 Ipca Laboratories Ltd MR.PRANAY GODHA Key Management Personnel Any other transaction Post employment benefits of Directors Approved 1000000 0 0
76 Ipca Laboratories Ltd MR. PRASHANT GODHA Key Management Personnel Any other transaction Post employment benefits of Directors Approved 500000 0 0
77 Ipca Laboratories Ltd IPCA PHARMA NIGERIA LTD. Subsidiaries Advance Approved 300000 0 0
Total value of transaction during the reporting period -682000000